ABVC BIOPHARMA INC

ABVCNASDAQ

🏆 #4609 by market capUS Equity

$638.44▲ $43.09 (+6.75%)

Simulated price

🔔

Track ABVC

Get earnings, price moves & breaking news on Telegram

Track

24h▲ 6.8%

7d—

14d—

30d—

ytd—

1y—

🏦Market Cap

$35M

Small Cap

📈Revenue Growth (YoY)

+103.4%

High Growth

📊Gross Margin

0.3%

Thin

💵FCF Margin

21.3%

Strong

⚖️P/S Ratio

44.1x

Expensive

Otter Score

Weak

No chart data available for ABVC.

Trading Snapshot

Day Range: $631.36 – $643.73
52-Week Range: $0.71 – $3.40
Volume: $2.84B
Avg Volume: $3.17B
Shares Outstanding: 26.0M
Next Earnings: Oct 19, 2026

Fundamentals Snapshot

Annual Revenue: $797,920
Last Q Revenue: $180,237
P/E Ratio: —
P/S Ratio: 44.1x
EPS (TTM): $-0.32
Dividend Yield: —
Dilution (1yr): +74.6%

Why Investors Own ABVC

✓High-growth profile — revenue up +49.5% YoY with expanding US Equity exposure.
✓Healthy economics — 29% gross margin and 7% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

ABVC BIOPHARMA INC

ABVC

Financial Trends

Revenue

$0▼ −100.0% YoY

Gross Margin

99.9%▼ −201.7% YoY

Operating Income

−$7M▲ +52.0% YoY

Free Cash Flow

−$3M▲ +65.1% YoY

Shares Outstanding

23.3M▲ +74.6% YoY

Net Cash

−$3M▼ −$451K YoY

StockOtter · stockotter.space

About ABVC BIOPHARMA INC

ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key candidates: ABV-1501, currently undergoing Phase I/II clinical trials, is being developed as a combination treatment for triple-negative breast cancer. ABV-1504 has successfully completed Phase II clinical trials for major depressive disorders. ABV-1505 is progressing through Phase II clinical studies for attention deficit hyperactivity disorder (ADHD). ABV-1703 has concluded its Phase I clinical trials for the treatment of pancreatic cancer. ABV-1702 has also finished Phase I clinical investigations for myelodysplastic syndromes. ABV-1601 is in Phase I/II clinical trials, aimed at alleviating depression in individuals with cancer. ABV-1701 Vitargus is in development to treat conditions such as retinal detachment or vitreous hemorrhage. ABVC BioPharma maintains strategic alliances, including a co-development arrangement with Rgene Corporation, alongside collaborative agreements with BioHopeKing Corporation and BioFirst Corporation. The company's headquarters are located in Fremont, California, and it operates as a subsidiary of YuanGene Corporation.

🦦